Ubrogepant

Introduction Overview

Generic Name

ubrogepant

Brand Name

Ubrelvy

Dosage Form

tablet

Drug Class

CGRP inhibitors

Pharmacokinetics

Absorption:
Ubrogepant is rapidly absorbed following oral administration, with peak plasma concentrations (Cmax) typically achieved approximately 1.5 to 2 hours post-dose. This rapid absorption contributes to its relatively quick onset of action in acute migraine treatment. The oral bioavailability of ubrogepant is moderate, and food intake does not significantly affect the overall extent of absorption, though high-fat meals may slightly delay the time to peak concentration without reducing efficacy. The absorption phase is essential to promptly achieve therapeutic plasma levels necessary for mitigating migraine symptoms.

Distribution:
Once absorbed, ubrogepant exhibits moderate plasma protein binding (~90%), primarily to albumin, influencing its distribution profile. The volume of distribution is estimated at approximately 350 liters, indicating extensive tissue distribution beyond the vascular compartment. Ubrogepant demonstrates the ability to penetrate tissues effectively, including the central nervous system, which is relevant to its mechanism targeting neuronal CGRP receptors. Its distribution is influenced by factors such as age, hepatic function, and concurrent medications, which may alter plasma levels.

Metabolism:
Ubrogepant undergoes hepatic metabolism predominantly via the cytochrome P450 enzyme CYP3A4 system. The primary metabolic pathways include oxidation and subsequent conjugation processes. The metabolic profile indicates extensive first-pass metabolism, and significant drug-drug interactions may occur with both strong inhibitors and inducers of CYP3A4. Notably, co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole) is contraindicated because they markedly increase plasma concentrations of ubrogepant, potentially raising the risk of adverse effects. Conversely, CYP3A4 inducers (e.g., rifampin, carbamazepine) can reduce ubrogepant exposure and efficacy.

Elimination:
The elimination of ubrogepant is primarily via biliary/fecal excretion (approximately 42%) and renal excretion (approximately 6%). The terminal half-life averages 5 to 7 hours, allowing for effective dosing every 24 hours for acute treatment without significant accumulation. Renal clearance is minimal; however, hepatic impairment can affect elimination and may necessitate dosage adjustments. The drug does not appear to undergo significant enterohepatic recycling. Understanding elimination is crucial for determining dosing intervals and for assessing suitability in patients with hepatic or renal dysfunction.

Dosage Forms

Available Dosage Forms:
Ubrogepant is available exclusively as oral tablets formulated for acute migraine treatment. The tablet is designed for rapid oral absorption. Specific dosage strengths include a 50 mg tablet and a 100 mg tablet, allowing flexibility in dosing based on clinical response and patient tolerance.

Dosages for Adults and Adolescents:
Ubrogepant is approved for use in adults for the acute treatment of migraine attacks with or without aura. The recommended initial dose is 50 mg orally, which may be administered with or without food. If the migraine symptoms persist or recur, a second dose of 50 mg or 100 mg may be taken at least 2 hours after the first dose, with a maximum dosing limit of one or two tablets in 24 hours depending on the dose strength used. It is important not to exceed two doses in a 24-hour period. There is insufficient evidence regarding safety and efficacy in pediatric populations; thus, ubrogepant is not approved for use in children or adolescents under 18 years of age.

Specific Patient Populations:
In patients with mild to moderate hepatic impairment, no dosage adjustment is typically required; however, use with caution in moderate hepatic impairment is advised. It is not recommended in severe hepatic impairment due to limited data. For patients with renal impairment, no dose adjustment is necessary for mild or moderate impairment; however, caution is advised due to limited experience. There are no established guidelines for dosage modifications in elderly patients, but clinical considerations include monitoring for tolerability and potential interactions. Ubrogepant should be used cautiously in patients consuming grapefruit products or taking CYP3A4 inhibitors such as verapamil, cyclosporine, ciprofloxacin, fluconazole, or fluvoxamine, especially when considering redosing within 24 hours.

Mechanism Of Action

Ubrogepant functions primarily as a highly selective antagonist of the calcitonin gene-related peptide (CGRP) receptor. CGRP is a 37-amino acid neuropeptide widely distributed in the central and peripheral nervous systems and plays a critical role in migraine pathophysiology by mediating vasodilation and transmitting pain signals. During migraine attacks, elevated CGRP levels contribute to neurogenic inflammation, vasodilation of cranial blood vessels, and heightened nociceptive transmission, leading to the characteristic pain and symptoms of migraine.

By selectively binding to and inhibiting the CGRP receptor, ubrogepant prevents CGRP from activating its receptor on trigeminal neurons and vascular smooth muscle. This blockade results in decreased vasodilation, reduced neurogenic inflammation, and interruption of the pain signaling pathways responsible for migraine headaches. Unlike triptans, which act on serotonin 5-HT1B/1D receptors causing vasoconstriction and potential cardiovascular side effects, ubrogepant offers a more targeted mechanism with potentially fewer vascular risks.

At the cellular level, ubrogepant's antagonism of CGRP receptors inhibits downstream intracellular cyclic AMP production and the release of pro-inflammatory mediators. This biochemical interaction mitigates sensitization of pain pathways and reduces the transmission of migraine-associated sensory stimuli such as photophobia and phonophobia. Clinical trials have demonstrated that treatment with ubrogepant leads to significant reductions in migraine pain and associated symptoms within two hours of dosing, correlating with its molecular mechanism.

Comparative studies suggest that ubrogepant, as a small-molecule CGRP receptor antagonist, provides effective acute migraine relief with a favorable safety profile, especially in patients contraindicated for triptans due to cardiovascular conditions. Ongoing research continues to elucidate its long-term efficacy and potential utility in broader migraine management strategies.

Pharmacological Actions

Selective antagonism of calcitonin gene-related peptide (CGRP) receptors.
Inhibition of neurogenic inflammation associated with migraine pathophysiology.
Reduction of cranial vasodilation contributing to migraine pain relief.
Modulation of nociceptive transmission in trigeminal neurons.
Rapid onset of action with therapeutic effects observed within 2 hours post-dose.
Non-vasoconstrictive mechanism, offering a safer profile than triptans for patients with cardiovascular risk.
Orally bioavailable small-molecule that crosses the blood-brain barrier to exert central effects.
Minimal interaction with serotonin receptors, reducing risk of serotonergic side effects.

Therapeutic Or Clinical Uses

Acute treatment of migraine attacks with or without aura in adults.
Provides relief of migraine pain within 2 hours of oral administration.
Reduction of migraine-associated symptoms including nausea, photophobia, and phonophobia.
Alternative treatment option for patients contraindicated for or intolerant to triptans.
Not indicated for prevention of migraine attacks.
Potential utility in patients with cardiovascular risk where triptans are contraindicated.
Treatment option when rapid onset of symptomatic relief is desired.
Suitable for patients unable to tolerate traditional migraine analgesics or NSAIDs.
Used in clinical practice to manage moderate to severe migraine episodes.
Prescribed for patients seeking non-opioid migraine therapy.
Valuable in patients with episodic migraines needing intermittent acute therapy.

Side Or Adverse Effects

Nausea is the most commonly reported adverse effect.
Somnolence or sleepiness occurring in some patients.
Mild to moderate fatigue reported occasionally.
Dizziness in a minority of patients.
Rare hypersensitivity reactions including rash.
Potential for gastrointestinal discomfort such as abdominal pain or indigestion.
No significant vasoconstrictive adverse events reported.
Minimal incidence of liver enzyme elevations; monitoring recommended in hepatic impairment.
Low risk of medication overuse headache compared to triptans.
No reported serious cardiac adverse events in clinical trials.
Potential mild elevations in alanine aminotransferase (ALT) in rare cases.
Headache recurrence or insufficient response may occur, not classified as adverse effect.

Precautions

Use cautiously in patients with moderate to severe hepatic impairment.
Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, or itraconazole.
Limit dosing frequency to a maximum of two doses per 24-hour period.
Avoid use within 24 hours of consuming grapefruit or grapefruit juice.
Patients should inform healthcare providers of all concomitant medications due to potential interactions.
Monitor liver function periodically during prolonged use.
Patients with severe renal impairment should be monitored closely.
Safety and efficacy have not been established in pediatric populations; avoid use under 18 years of age.
Caution advised when administered with CYP3A4 inducers which may reduce therapeutic effect.
Pregnant or breastfeeding patients should consult healthcare providers before use due to insufficient safety data.
Avoid excessive dosing beyond labeled recommendations to prevent toxicity.
Patients should maintain a headache diary to assess treatment effectiveness and usage frequency.
Use is not recommended for chronic migraine prevention.
Consider patient history of hypersensitivity reactions when prescribing.
Not recommended in patients currently taking opioids or barbiturates without medical supervision.

Warnings

Contraindicated with strong CYP3A4 inhibitors due to risk of increased ubrogepant plasma levels and toxicity.
Do not exceed two doses within a 24-hour period to minimize adverse effects.
Potential risk of elevated liver enzymes; discontinue if clinically significant elevations occur.
Limited safety data in pregnant or lactating women; use only if benefits outweigh risks.
Not a preventive treatment; improper chronic use may lead to medication-overuse headaches.
Risk of slowed drug metabolism with concurrent CYP3A4 inhibitors leading to increased side effects.
Avoid in patients with known hypersensitivity to ubrogepant or any tablet components.
Caution advised in patients with severe renal or hepatic impairment due to altered pharmacokinetics.
Use in combination with grapefruit or grapefruit juice may increase ubrogepant exposure contraindicated.
Delay second dosing by at least 2 hours; redosing sooner can increase adverse effects.
Patients should seek immediate medical attention if signs of hypersensitivity or allergic reactions occur.
In the absence of robust pediatric data, use in children is not recommended.
Concurrent use with strong CYP3A4 inducers may reduce effectiveness; dose adjustment may be necessary.
Avoid concurrent administration with drugs that prolong QT interval until more data are available.
No addiction or abuse potential identified but patient monitoring is advised.

Contraindication

Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole).
Known hypersensitivity to ubrogepant or any excipients in the tablet formulation.
Use in pediatric patients under 18 years due to lack of safety and efficacy data.
Patients with severe hepatic impairment owing to insufficient clinical safety data.
Patients who consume grapefruit or grapefruit juice and plan to redose within 24 hours.
Concurrent use with medications that have severe interaction risk without capability for monitoring.
Should not be used for migraine prevention.
Avoid use in patients with history of allergic reactions to CGRP receptor antagonists.
Contraindicated in patients with significant concomitant medications that cannot be changed to avoid interactions.
Patients with severe renal impairment unless benefits outweigh risks.
Combination with strong CYP3A4 inducers without dose modification is contraindicated.
In patients with unstable cardiovascular disease until further data are available.
Not indicated for cluster headache or other non-migraine headache disorders.
Use contraindicated in pregnancy unless benefits justify potential fetal risks.
Contraindicated in breastfeeding women without physician recommendation.

Drug Interactions

Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole) significantly increase ubrogepant plasma levels; coadministration is contraindicated.
Moderate CYP3A4 inhibitors (verapamil, cyclosporine, ciprofloxacin, fluconazole, fluvoxamine) increase exposure; avoid redosing within 24 hours after consuming these agents.
CYP3A4 inducers (rifampin, phenytoin, barbiturates, St. John’s Wort) reduce ubrogepant plasma concentrations, potentially reducing efficacy.
Interactions reported with carvedilol and eltrombopag warrant clinical monitoring when coadministered.
Potential pharmacodynamic interactions with drugs affecting central nervous system function such as fluvoxamine.
Co-administration with substrates of CYP2C9 or CYP2D6 appears not to be clinically significant.
No significant interactions reported with NSAIDs or acetaminophen used concomitantly for migraine.
No established interactions with oral contraceptives or hormone replacement therapy.
Use caution with medications metabolized by the liver, particularly CYP3A4, to avoid altered drug levels.
Concurrent use with curcumin supplements may affect metabolism; clinical significance unknown.
Minimal interaction with drugs that modulate serotonin receptors, avoiding serotonergic syndrome risk.
No significant effect on warfarin pharmacokinetics observed; however, monitoring is advised.
Avoid grapefruit juice consumption when planning to redose within 24 hours due to interaction risk.
Potential interaction with CYP3A4 substrates necessitates dose adjustments when used together.
Consider dose adjustment or alternative therapies when interacting drugs cannot be discontinued.

Preparations Of The Drug

Ubrogepant is formulated as an oral tablet for acute migraine treatment.
Available in 50 mg and 100 mg strengths to provide dosing flexibility.
Inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.
Manufactured by Forest Laboratories Ireland Ltd., Dublin, Ireland.
Distributed by Allergan USA, Inc., Madison, NJ 07940.
Designed for convenient oral administration with or without food.
Packaged in blister packs or bottles suitable for outpatient dispensing.
Non-controlled substance classification, facilitating prescribing and dispensing.
Stable at room temperature between 68ºF to 77ºF (20ºC to 25ºC); protect from moisture and excessive heat.
Tablets are film-coated to enhance stability and patient compliance.
No nasal, injectable, or extended-release formulations currently available.
Single-dose packaging aids in precise dosing and adherence.
Not formulated for pediatric use or alternative routes of administration.
Storage requires keeping medication out of reach of children.
Patient assistance programs and manufacturer coupons may be available to lessen cost burden.